Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia.
Alena MalyukovaMari LahnalampiTon Falqués-CostaPetri PölönenMikko SipolaJuha MehtonenSusanna TeppoKaren AkopyanJohanna ViiliainenOlli LohiAnna K Hagström-AnderssonMerja HeinäniemiOlle SangfeltPublished in: Genome biology (2024)
Collectively, our findings provide new insights into the tight connectivity of gene regulatory programs associated with cell cycle and cell fate regulation, and a rationale for sequential administration of WEE1 inhibitors with low toxicity inhibitors of pre-BCR signaling or metabolism.
Keyphrases
- cell cycle
- cell fate
- acute lymphoblastic leukemia
- cell proliferation
- public health
- papillary thyroid
- allogeneic hematopoietic stem cell transplantation
- blood brain barrier
- oxidative stress
- clinical trial
- transcription factor
- cancer therapy
- tyrosine kinase
- squamous cell carcinoma
- emergency department
- functional connectivity
- resting state
- multiple sclerosis
- gene expression
- combination therapy
- copy number
- adverse drug